BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics


BioXcel Therapeutics, Inc. (BTAI)

Today's Latest Price: $45.70 USD

0.27 (0.59%)

Updated Dec 4 4:00pm

Add BTAI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

BTAI Stock Price Chart Interactive Chart >

Price chart for BTAI

BTAI Price/Volume Stats

Current price $45.70 52-week high $71.50
Prev. close $45.43 52-week low $5.58
Day low $44.50 Volume 207,600
Day high $46.03 Avg. volume 578,324
50-day MA $48.35 Dividend yield N/A
200-day MA $42.52 Market Cap 1.11B

BioXcel Therapeutics, Inc. (BTAI) Company Bio


BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.


BTAI Latest News Stream


Event/Time News Detail
Loading, please wait...

BTAI Latest Social Stream


Loading social stream, please wait...

View Full BTAI Social Stream

Latest BTAI News From Around the Web

Below are the latest news stories about BioXcel Therapeutics Inc that investors may wish to consider to help them evaluate BTAI as an investment opportunity.

BioXcel Therapeutics EPS misses by $0.28

BioXcel Therapeutics (BTAI): Q2 GAAP EPS of -$1.06 misses by $0.28.Cash and cash equivalents of $65.5M"We look forward to submitting an NDA for BXCL501 to the FDA in the first quarter of 2021," stated Vimal Mehta, CEO. Press Release...

Seeking Alpha | August 14, 2020

BioXcel Therapeutics' (BTAI) CEO Vimal Mehta on Q2 2020 Results - Earnings Call Transcript

BioXcel Therapeutics, Inc. (BTAI) Q2 2020 Earnings Conference Call August 14, 2020 8:30 AM ET Company Participants Vimal Mehta – Chief Executive Officer Michael Stanton – Controller Rob Risinger – Senior Vice President-Clinical Development Will Kane – Chief Commercial Officer Reina Benabou – Chief Development Officer Conference Call Participants Geoff...

SA Transcripts on Seeking Alpha | August 14, 2020

Earnings Scheduled For August 14, 2020

Companies Reporting Before The Bell • DraftKings Inc. (NASDAQ: DKNG ) is expected to report quarterly loss at $0.19 per share on revenue of $63.90 million. • RumbleON Inc. (NASDAQ: RMBL ) is expected to report quarterly loss at $4.56 per share on revenue of $107.35 million. • Celsion Inc. (NASDAQ: CLSN ) is estimated to report quarterly loss at $0.14 per share on revenue of $80.00 thousand. • Ocugen Inc. (NASDAQ: OCGN ) is expected to report earnings for its second quarter. • American Shared Hospital Services Common Stock Inc. (AMEX: AMS ) is expected to report earnings for its second quarter. • AYRO Inc. (NASDAQ: AYRO ) is estimated to report earnings for its second quarter. • BIO-key International Inc. (NASDAQ: BKYI ) is expected to report quarterly loss at $0.03 per share on revenue ...

Benzinga | August 14, 2020

BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock

NEW HAVEN, Conn., July 28, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 4,000,000 shares of common stock at a public offering price of $50.00 per share. In addition, certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Gross proceeds to BTI from the offering are expected to be $200 million, before deducting underwriting discounts and commissions and offering expenses. The Company will not receive any of the proceeds from any sale of shares in this offering by the...

Yahoo | July 29, 2020

BioXcel Therapeutics Announces Proposed Public Offering of Common Stock

NEW HAVEN, Conn., July 27, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage…

GlobeNewswire | July 27, 2020

Read More 'BTAI' Stories Here

BTAI Price Returns

1-mo -15.92%
3-mo 11.33%
6-mo -4.23%
1-year 619.69%
3-year N/A
5-year N/A
YTD 212.80%
2019 278.50%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8457 seconds.